Capillary action through synthetic mesh

Global Hernia Mesh Devices Market Size, Share & Trends Analysis Report 2023: Market to Reach $8.3 Billion by 2030 - Innovation in Enhancing Patient Outcomes Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 13, 2023
Medical Supplies, Medical Devices, Health, Surgery, General Health, Biotechnology, Incidence, Femoral hernia, Hernia, Capillary action through synthetic mesh, Prevalence, Inguinal hernia, USD, Biomesh, Growth, Incisional hernia, Operation Time, Patient, Thermoplastic, Pharmaceutical industry

The "Hernia Mesh Devices Market Size, Share & Trends Analysis Report By Hernia Type (Inguinal Hernia, Incisional Hernia, Femoral Hernia), By Mesh Type (Biologic Mesh, Synthetic Mesh), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hernia Mesh Devices Market Size, Share & Trends Analysis Report By Hernia Type (Inguinal Hernia, Incisional Hernia, Femoral Hernia), By Mesh Type (Biologic Mesh, Synthetic Mesh), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global hernia mesh devices market size is expected to reach USD 8.3 billion by 2030.
  • Additionally, the market benefits from a favorable reimbursement scenario, which encourages patients to opt for hernia surgeries, further boosting market growth.
  • Among hernia types, inguinal hernia repair devices hold a substantial market share, thanks to the wide range of available mesh products designed specifically for inguinal repair.

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

Retrieved on: 
Thursday, March 16, 2023
Anatomy, Surgeon, United Kingdom, Timmer, BRAVO, Risk, Infection, Case series, Hernia, Patient, S. Sivaraj, Capillary action through synthetic mesh, Biosynthesis, Consultant, Cohort (statistics), Publication, D. P, DOI, Use, Recurrence, Medical imaging, Dentistry, Victor Trotsyuk, Claessen

(NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.

Key Points: 
  • (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.
  • It is estimated that over two million hernia repairs will be performed this year within the United States, Europe, and the United Kingdom.
  • Launched in June 2016, OviTex has been rigorously studied in the clinical setting since its commercialization.
  • * Clinical Outcomes of Open Abdominal Wall Reconstruction with the Use of a Polypropylene Reinforced Tissue Matrix: A Multicenter Retrospective Study.